Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Company entered into negotiations with third party to transfer lease obligationNon-binding letter of intent signed60-day exclusivity period to finalize detailsA successful transaction would lead to a...
-
MORRISVILLE, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has recently completed patient recruitment in the Company’s...
-
Preclinical data published in Antiviral ResearchStudy conducted by Drs. N.S. Banerjee, L.T. Chow and T.R. Broker at The University of Alabama at BirminghamFindings reinforce anti-viral mechanism of...
-
More than 50 percent of total expected patients now enrolledVirtually all of the clinical sites now active Discipline and execution focus remain of equal importance to recruitment activity ...
-
Expansion of the existing relationship with MedPharm around formulation scienceManufacturing agreement established for production of proprietary drug substancePartner network now includes those...
-
MORRISVILLE, N.C., June 13, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it will participate in the 2019 JMP Securities Life Sciences Conference...
-
MORRISVILLE, N.C., June 06, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN) today announced it has received notification from The Nasdaq Stock Market LLC ("Nasdaq")...
-
Phase 3 pivotal program commences and underwayInvestigative sites now activated and enrollment activities actionedAnticipated patient demand managed with a highly disciplined approach to trial...
-
MORRISVILLE, N.C., May 31, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN) today announced that it will hold its 2019 Annual Meeting of Stockholders on Wednesday, July...
-
MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the...